<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104776</url>
  </required_header>
  <id_info>
    <org_study_id>0209-01</org_study_id>
    <nct_id>NCT04104776</nct_id>
  </id_info>
  <brief_title>A Study of CPI-0209 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constellation Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Constellation Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in
      patients with advanced solid tumors alone and in combination with other therapies. CPI-0209
      is a small molecule inhibitor of EZH2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Frequency of Dose-limiting toxicities (DLTs)</measure>
    <time_frame>DLTs assessed during Cycle 1 (first 28 days on study for monotherapy and first 21 days for combination therapy)</time_frame>
    <description>The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CPI-0209 as monotherapy and in combination with irinotecan in patients with advanced solid tumors</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-0209 will be dosed once per day orally in 28 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-0209 will be dosed once per day orally in 21 day cycles. Irinotecan iv will be dosed on day 1 of every cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-0209</intervention_name>
    <description>CPI-0209 alone</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>CPI-0209 in combination with irinotecan</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Life expectancy of ≥ 12 weeks

          -  Recovered to baseline or Grade ≤ 1 severity from toxicity related to prior treatments,
             unless AEs are clinically non-significant and/or stable on supportive therapy

          -  ECOG 0-1

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate liver function

        Exclusion Criteria:

          -  Previous solid organ or hematopoietic cell transplant

          -  Known brain metatstases

          -  Known Gilbert's disease

          -  Prior EZH2 inhibitor

          -  Concomitant medication(s) or food or beverage that are moderate or strong CYP3A
             inducers or inhibitors within 2 weeks prior to the first dose of study drug

          -  Clinically significant cardiovascular disease

          -  Major surgery within 4 weeks

          -  GI disorders affecting absorption

          -  Uncontrolled infection

          -  Suspected pneumonitis or interstitial lung disease

          -  Known additional malignancy that is active and/or progressive requiring treatment

          -  Known HIV or active hepatitis

          -  Chronic liver disease

          -  Women of child bearing potential and men with reproductive potential, if they are -
             unwilling to use adequate contraception while on study therapy and for 3 months
             thereafter

          -  Patients unwilling or unable to comply with this study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon S Skibinski-Preston, MPH</last_name>
      <phone>616-954-5552</phone>
      <email>shannon.skibinski@startmidwest.com</email>
    </contact>
    <contact_backup>
      <last_name>Yvette Cole, RN</last_name>
      <phone>616-389-1652</phone>
      <email>yvette.cole@startmidwest.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nehal Lakhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <phone>551-996-4725</phone>
      <email>chelsea.mccabe@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Rivas, RN</last_name>
      <phone>210-593-5943</phone>
      <email>karla.rivas@startsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Choi, RN</last_name>
      <phone>210-593-2547</phone>
      <email>carrie.choi@startsa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Drew Rasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
      <email>AM7BD@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

